Bharat Biotech Submits Data From Covaxin's Phase-III Clinical Trial To DCGI: ReportBharat Biotech’s COVAXIN, India’s first indigenous vaccine against coronavirus. (Swarajya Magazine)

Hyderabad-based Bharat Biotech is said to have submitted the data from the Phase III clinical trials of Covaxin to the Drugs Controller General of India (DCGI) over the bygone weekend, reports Economic Times.

It should be noted that in a press briefing some days ago, NITI Aayog's member (Health) Dr V K Paul had said that Bharat Biotech would be submitting the data within seven to eight days. Dr V K Paul also heads the Government's COVID-19 task force.

Developed in close coordination with the Indian Council of Medical Research (ICMR) and Pune-based National Institute of Virology, Bharat Biotech's Covaxin is one of the only three COVID-19 vaccines being administered to the population in the country right now.

The development comes at a time when Dr Krishna Ella-led company is in the midst of significantly expanding its production capacity for Covaxin.

It should be noted that Covaxin is the only indigenously developed vaccine being used in the country at the moment. The others being Russian Sputnik V and AstraZeneca's vaccine which is manufactured and sold in India by Serum Institute of India under the name of Covishield.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber